Warburg Pincus trims stake in China Biologic

The US private equity firm raises $241.5 million after paring stake in the Nasdaq-listed biopharmaceutical firm.

Warburg Pincus has raised $241.5 million following a share sale in China Biologic Products.

The US private equity firm saw its stake decrease from 44.2% to 34% after the sale, according to a source close to the deal.

The sale in the Nasdaq-listed biopharmaceutical company has been marketed for the past few days in the US, which contributed to a decline in share price performance. After hitting $120.85 per unit on June 3, shares fell by 13% up to June 10.

Sources close to the deal note that it’s very typical for a drop in performance before a share-sale in the US....

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222